Q1 EPS Forecast for USANA Health Sciences Reduced by Analyst

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities researchers at Sidoti Csr reduced their Q1 2025 EPS estimates for USANA Health Sciences in a research report issued on Tuesday, February 18th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings of $0.77 per share for the quarter, down from their prior forecast of $0.84. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q2 2025 earnings at $0.68 EPS, Q3 2025 earnings at $0.70 EPS, Q4 2025 earnings at $0.74 EPS, FY2025 earnings at $2.89 EPS, Q1 2026 earnings at $0.89 EPS, Q2 2026 earnings at $0.86 EPS, Q3 2026 earnings at $0.90 EPS and FY2026 earnings at $3.59 EPS.

Several other equities research analysts have also weighed in on the stock. DA Davidson increased their target price on shares of USANA Health Sciences from $35.00 to $38.00 and gave the stock a "neutral" rating in a report on Thursday, January 2nd. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th.

USANA Health Sciences Trading Up 2.7 %

Shares of NYSE:USNA traded up $0.87 during mid-day trading on Thursday, reaching $32.65. The stock had a trading volume of 126,423 shares, compared to its average volume of 133,626. The firm has a market cap of $622.31 million, a PE ratio of 11.54, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The firm has a 50 day simple moving average of $33.81 and a two-hundred day simple moving average of $36.73. USANA Health Sciences has a twelve month low of $30.13 and a twelve month high of $50.32.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in USNA. Creative Planning acquired a new position in USANA Health Sciences during the third quarter valued at approximately $394,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of USANA Health Sciences by 14,068.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company's stock valued at $1,472,000 after buying an additional 38,547 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of USANA Health Sciences by 13.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company's stock valued at $4,702,000 after buying an additional 14,756 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of USANA Health Sciences by 44.1% in the third quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company's stock valued at $336,000 after buying an additional 2,713 shares in the last quarter. Finally, KBC Group NV increased its holdings in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company's stock worth $40,000 after buying an additional 519 shares during the last quarter. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.